DDInter1534 DDInter927
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Propafenone {u} (Compound) resembles {v} (Compound) Atomoxetine
Propafenone {u} (Compound) resembles {v} (Compound) Benazepril
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salmeterol
Propafenone {u} (Compound) binds {v} (Gene) CYP2C9
Propafenone {u} (Compound) upregulates {v} (Gene) KIAA0355
Propafenone {u} (Compound) downregulates {v} (Gene) IFRD2
Propafenone {u} (Compound) causes {v} (Side Effect) Lupus-like syndrome
Propafenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Propafenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Propafenone (Compound) resembles Atomoxetine (Compound)
Propafenone (Compound) resembles Benazepril (Compound)
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Propafenone (Compound) binds CYP2C9 (Gene)
Propafenone (Compound) upregulates KIAA0355 (Gene)
Propafenone (Compound) downregulates IFRD2 (Gene)
Propafenone (Compound) causes Lupus-like syndrome (Side Effect)
Propafenone may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Propafenone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol